Functional Role for Cannabinoids in Respiratory Stability During Sleep

Carley, David W.; Paviovic, Sasa; Janelidze, Marika; Radulovački, Miodrag

doi:10.1093/sleep/25.4.388

Cited by 70 publications

(77 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, cannabinoids have been proposed as a potential treatment for obstructive sleep apnea. 37 Cocaine, which has the potential to produce microvascular brain injury, was not associated with SDB in the present study. Another limitation of this study is that drug use reports were retrospective, and self-reported prior drug use is subject to error.…”

Section: Resultssupporting

confidence: 37%

Sleep apnea in young abstinent recreational MDMA (“ecstasy”) consumers

McCann¹,

Sgambati

Schwartz³

et al. 2009

Neurology

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 37%

Sleep apnea in young abstinent recreational MDMA (“ecstasy”) consumers

McCann¹,

Sgambati

Schwartz³

et al. 2009

Neurology

View full text Add to dashboard Cite

show abstract

“…Several effects observed in animal studies provide the basis for further research, among them are effects against diarrhea in mice [313] and stabilization of respiration in sleep-related breathing disorders (e.g. apnea) [314]. Cannabinoids were effective in an animal model of attentiondeficit hyperactivity disorder (ADHD), in the spontaneously hypertensive-rat (SHR) [315].…”

Section: Preclinical Mechanistic Studiesmentioning

confidence: 99%

Cannabinoids

Grotenhermen

2005

CDTCNSND

110

View full text Add to dashboard Cite

Since the discovery of an endogenous cannabinoid system, research into the pharmacology and therapeutic potential of cannabinoids has steadily increased. Two subtypes of G-protein coupled cannabinoid receptors, CB(1) and CB(1), have been cloned and several putative endogenous ligands (endocannabinoids) have been detected during the past 15 years. The main endocannabinoids are arachidonoyl ethanolamide (anandamide) and 2-arachidonoyl glycerol (2-AG), derivatives of arachidonic acid, that are produced "on demand" by cleavage of membrane lipid precursors. Besides phytocannabinoids of the cannabis plant, modulators of the cannabinoid system comprise synthetic agonists and antagonists at the CB receptors and inhibitors of endocannabinoid degradation. Cannabinoid receptors are distributed in the central nervous system and many peripheral tissues, including immune system, reproductive and gastrointestinal tracts, sympathetic ganglia, endocrine glands, arteries, lung and heart. There is evidence for some non-receptor dependent mechanisms of cannabinoids and for endocannabinoid effects mediated by vanilloid receptors. Properties of CB receptor agonists that are of therapeutic interest include analgesia, muscle relaxation, immunosuppression, anti-inflammation, antiallergic effects, improvement of mood, stimulation of appetite, antiemesis, lowering of intraocular pressure, bronchodilation, neuroprotection and antineoplastic effects. The current main focus of clinical research is their efficacy in chronic pain and neurological disorders. CB receptor antagonists are under investigation for medical use in obesity and nicotine addiction. Additional potential was proposed for the treatment of alcohol and heroine dependency, schizophrenia, conditions with lowered blood pressure, Parkinson's disease and memory impairment in Alzheimer's disease.

show abstract

“…Circulating endocannabinoids are increased in obese patients, particularly with visceral obesity and in patients with insulin resistance [7][8][9]. Endocannabinoids may be involved in the regulation of breathing patterns during sleep and in sleep rhythms [10,11]. In a previous report, AEA was not increased in obese patients with mild OSA symptoms and normal blood pressure compared to controls [12].…”

Section: Introductionmentioning

confidence: 99%